Rakovina Therapeutics (TSXV:RKV) Total Liabilities : C$2.23 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics Total Liabilities?

Rakovina Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 was C$2.23 Mil.

Rakovina Therapeutics's quarterly Total Liabilities increased from Mar. 2024 (C$1.67 Mil) to Jun. 2024 (C$2.42 Mil) but then declined from Jun. 2024 (C$2.42 Mil) to Sep. 2024 (C$2.23 Mil).

Rakovina Therapeutics's annual Total Liabilities declined from Dec. 2021 (C$0.11 Mil) to Dec. 2022 (C$0.11 Mil) but then increased from Dec. 2022 (C$0.11 Mil) to Dec. 2023 (C$1.49 Mil).

Rakovina Therapeutics Total Liabilities Historical Data

The historical data trend for Rakovina Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Total Liabilities Chart

Rakovina Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Total Liabilities

0.11

1.49

Rakovina Therapeutics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial										1.50	1.49	1.67	2.42	2.23

Rakovina Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Rakovina Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.155	+	(1.333	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.49

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	5.148	-	3.66
	=	1.49

Rakovina Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.838	+	(1.396	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.23

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	5.308	-	3.074
	=	2.23

Rakovina Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Rakovina Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5

Website

https://www.rakovinatherapeutics.com

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.

Executives

Jeffrey Bacha	Senior Officer
Mads Daugaard	Senior Officer
Alfredo De Lucrezia	Director, Senior Officer
David Hyman	Senior Officer
John Michael Langlands	Senior Officer

Rakovina Therapeutics Headlines

No Headlines